TLR7 and 9 agonists are highly effective mucosal adjuvants for norovirus virus-like particle vaccines

Hjelm, Brooke E.; Kilbourne, Jacquelyn; Herbst-Kralovetz, Melissa M.
February 2014
Human Vaccines & Immunotherapeutics;Feb2014, Vol. 10 Issue 2, p1
Academic Journal
No abstract available.


Related Articles

  • Airway structural cells regulate TLR5-mediated mucosal adjuvant activity. Van Maele, L; Fougeron, D; Janot, L; Didierlaurent, A; Cayet, D; Tabareau, J; Rumbo, M; Corvo-Chamaillard, S; Boulenouar, S; Jeffs, S; Vande Walle, L; Lamkanfi, M; Lemoine, Y; Erard, F; Hot, D; Hussell, T; Ryffel, B; Benecke, A G; Sirard, J-C // Mucosal Immunology (1933-0219);May2014, Vol. 7 Issue 3, p489 

    Antigen-presenting cell (APC) activation is enhanced by vaccine adjuvants. Most vaccines are based on the assumption that adjuvant activity of Toll-like receptor (TLR) agonists depends on direct, functional activation of APCs. Here, we sought to establish whether TLR stimulation in...

  • Erratum.  // Journal of Infectious Diseases;Apr2011, Vol. 203 Issue 7, p1036 

    A correction to the article "Adjuvanted Intranasal Norwalk Virus-Like Particle Vaccine Elicits Antibodies and Antibody Secreting Cells that Express Homing Receptors in Mucosal and Peripheral Lymphoid Tissues" that was published in the 2010 issue is presented.

  • Intranasal Immunization with Influenza VLPs Incorporating Membrane-Anchored Flagellin Induces Strong Heterosubtypic Protection. Bao-Zhong Wang; Rui Xu; Fu-Shi Quan; Sang-Moo Kang; Li Wang; Compans, Richard W. // PLoS ONE;2010, Vol. 5 Issue 11, p1 

    We demonstrated previously that the incorporation of a membrane-anchored form of flagellin into influenza virus-like particles (VLPs) improved the immunogenicity of VLPs significantly, inducing partially protective heterosubtypic immunity by intramuscular immunization. Because the efficacy of...

  • The State of Norovirus Vaccines. Debbink, Kari; Lindesmith, Lisa C.; Baric, Ralph S. // Clinical Infectious Diseases;Jun2014, Vol. 58 Issue 12, p1746 

    While there is currently no approved norovirus vaccine, recent human clinical efficacy trials with virus-like particle–based vaccines have shown promise. Several additional norovirus vaccine platforms are also currently under development and will likely improve norovirus vaccines of the...

  • Mucosal adjuvants and delivery systems for protein-, DNA- and RNA-based vaccines. Vajdy, Michael; Srivastava, Indresh; Polo, John; Donnelly, John; O'Hagan, Derek; Singh, Manmohan // Immunology & Cell Biology;Dec2004, Vol. 82 Issue 6, p617 

    Almost all vaccinations today are delivered through parenteral routes. Mucosal vaccination offers several benefits over parenteral routes of vaccination, including ease of administration, the possibility of self-administration, elimination of the chance of injection with infected needles, and...

  • Mucosal Adjuvants. Harandi, Ali M.; Medaglini, Donata // Current HIV Research;Jun2010, Vol. 8 Issue 4, p330 

    The vast majority of pathogens invade the body through or establish infections in the mucosal tissues. Development of vaccines to combat mucosal infections represents a top priority. Mucosal immunization has recently attracted much interest as a means of generating protective immunity against...

  • Adjuvanted Intranasal Norwalk Virus-Like Particle Vaccine Elicits Antibodies and Antibody-Secreting Cells That Express Homing Receptors for Mucosal and Peripheral Lymphoid Tissues. El-Kamary, Samer S.; Pasetti, Marcela F.; Mendelman, Paul M.; Frey, Sharon E.; Bernstein, David I.; Treanor, John J.; Ferreira, Jennifer; Chen, Wilbur H.; Sublett, Richard; Richardson, Charles; Bargatze, Robert F.; Sztein, Marcelo B.; Tacket, Carol O. // Journal of Infectious Diseases;12/1/2010, Vol. 202 Issue 11, p1649 

    Background. Noroviruses cause significant morbidity and mortality from acute gastroenteritis in all age groups worldwide. Methods. We conducted 2 phase 1 double-blind, controlled studies of a virus-like particle (VLP) vaccine derived from norovirus GI.1 genotype adjuvanted with monophosphoryl...

  • The TLR4 agonist adjuvant SLA-SE promotes functional mucosal antibodies against a parenterally delivered ETEC vaccine. Liang, Hong; Poncet, David; Seydoux, Emilie; Rintala, Nicholas D.; Maciel, Milton; Ruiz, Sophie; Orr, Mark T. // NPJ Vaccines;5/28/2019, Vol. 4 Issue 1, pN.PAG 

    Many pathogens establish infection at mucosal surfaces such as the enteric pathogen Enterotoxigenic E. coli (ETEC). Thus, there is a pressing need for effective vaccination strategies that promote protective immunity at mucosal surfaces. Toll-like receptor (TLR) ligands have been extensively...

  • Microbial Translocation and B Cell Dysfunction in Human Immunodeficiency Virus Disease. Wei Jiang // American Journal of Immunology;2012, Vol. 8 Issue 2, p44 

    The gut mucosal barrier disrupted in HIV disease, resulting in increased systemic exposure to microbial products such as Lipo Polys Accharide (LPS). The association of enhanced microbial translocation and B cell dysfunction in HIV disease is not fully understood. High dose and short term...

  • Reprogramming the adjuvant properties of aluminum oxyhydroxide with nanoparticle technology. Orr, Mark T.; Khandhar, Amit P.; Seydoux, Emilie; Liang, Hong; Gage, Emily; Mikasa, Traci; Beebe, Elyse L.; Rintala, Nicholas D.; Persson, Karin H.; Ahniyaz, Anwar; Carter, Darrick; Reed, Steven G.; Fox, Christopher B. // NPJ Vaccines;1/3/2019, Vol. 4 Issue 1, pN.PAG 

    Aluminum salts, developed almost a century ago, remain the most commonly used adjuvant for licensed human vaccines. Compared to more recently developed vaccine adjuvants, aluminum adjuvants such as Alhydrogel are heterogeneous in nature, consisting of 1–10 micrometer-sized aggregates of...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics